Intriguingly, in tumors from patients with platinum-resistant ovarian cancer, TP53-GOF mutations were not detected, but we found the highest rate of unclassified TP53 mutations, including missense and splice site mutations with uncertain phenotypic effects. The gene discussed is TP53; the disease is ovarian carcinoma.